Literature DB >> 11970988

Prostaglandin E(2) inhibits IL-18-induced ICAM-1 and B7.2 expression through EP2/EP4 receptors in human peripheral blood mononuclear cells.

Hideo K Takahashi1, Hiromi Iwagaki, Tadashi Yoshino, Shuji Mori, Toshihiko Morichika, Hideyuki Itoh, Minori Yokoyama, Shinichiro Kubo, Eisaku Kondo, Tadaatsu Akagi, Noriaki Tanaka, Masahiro Nishibori.   

Abstract

Costimulatory molecules play important roles in immune responses. In the present study we investigated the effects of PGE(2) on the expression of ICAM-1, B7.1, and B7.2 on monocytes in IL-18-stimulated PBMC using FACS analysis. Addition of PGE(2) to PBMC inhibited ICAM-1 and B7.2 expression elicited by IL-18 in a concentration-dependent manner. We examined the involvement of four subtypes of PGE(2) receptors, EP1, EP2, EP3, and EP4, in the modulatory effect of PGE(2) on ICAM-1 and B7.2 expression elicited by IL-18, using subtype-specific agonists. ONO-AE1-259-01 (EP2R agonist) inhibited IL-18-elicited ICAM-1 and B7.2 expression in a concentration-dependent manner with a potency slightly less than that of PGE(2), while ONO-AE1-329 (EP4R agonist) was much less potent than PGE(2). The EP2/EP4R agonist 11-deoxy-PGE(1) mimicked the effect of PGE(2) with the same potency. ONO-D1-004 (EP1R agonist) and ONO-AE-248 (EP3R agonist) showed no effect on IL-18-elicited ICAM-1 or B7.2 expression. These results indicated that EP2 and EP4Rs were involved in the action of PGE(2). Dibutyryl cAMP and forskolin down-regulated ICAM-1 and B7.2 expression in IL-18-stimulated monocytes. As EP2 and EP4Rs are coupled to adenylate cyclase, we suggest that PGE(2) down-regulates IL-18-induced ICAM-1 and B7.2 expression in monocytes via EP2 and EP4Rs by cAMP-dependent signaling pathways. The fact that anti-B7.2 as well as anti-ICAM-1 Ab inhibited IL-18-induced cytokine production implies that PGE(2) may modulate the immune response through regulation of the expression of particular adhesion molecules on monocytes via EP2 and EP4Rs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11970988     DOI: 10.4049/jimmunol.168.9.4446

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  Relationship between inflammatory mediators, Aβ levels and ApoE genotype in Alzheimer disease.

Authors:  M Reale; M A Kamal; L Velluto; D Gambi; M Di Nicola; N H Greig
Journal:  Curr Alzheimer Res       Date:  2012-05       Impact factor: 3.498

2.  Short-Term Adjuvant Therapy with Terminalia arjuna Attenuates Ongoing Inflammation and Immune Imbalance in Patients with Stable Coronary Artery Disease: In Vitro and In Vivo Evidence.

Authors:  Divya Kapoor; Dimple Trikha; Rajesh Vijayvergiya; K K Parashar; Deepak Kaul; Veena Dhawan
Journal:  J Cardiovasc Transl Res       Date:  2015-04-01       Impact factor: 4.132

3.  Effect of ciprofloxacin-induced prostaglandin E2 on interleukin-18-treated monocytes.

Authors:  Hideo Kohka Takahashi; Hiromi Iwagaki; Dong Xue; Goutarou Katsuno; Sachi Sugita; Kenji Mizuno; Shuji Mori; Shinya Saito; Tadashi Yoshino; Noriaki Tanaka; Masahiro Nishibori
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

4.  E prostanoid 2 (EP2)/EP4-mediated suppression of antigen-specific human T-cell responses by prostaglandin E2.

Authors:  Mitsuhiro Okano; Yuji Sugata; Tazuko Fujiwara; Rie Matsumoto; Masahiro Nishibori; Kenji Shimizu; Megumi Maeda; Yoshinobu Kimura; Shin Kariya; Hisashi Hattori; Minehiko Yokoyama; Kosuke Kino; Kazunori Nishizaki
Journal:  Immunology       Date:  2006-07       Impact factor: 7.397

Review 5.  Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection.

Authors:  Jianxiong Jiang; Ray Dingledine
Journal:  Trends Pharmacol Sci       Date:  2013-06-21       Impact factor: 14.819

6.  Differential modulation in the functions of intestinal dendritic cells by long- and medium-chain fatty acids.

Authors:  Yoshikazu Tsuzuki; Jyunichi Miyazaki; Koji Matsuzaki; Yoshikiyo Okada; Ryota Hokari; Atsushi Kawaguchi; Shigeaki Nagao; Kazuro Itoh; Soichiro Miura
Journal:  J Gastroenterol       Date:  2006-03       Impact factor: 7.527

7.  The PGE2 EP2 receptor and its selective activation are beneficial against ischemic stroke.

Authors:  Muzamil Ahmad; Sofiyan Saleem; Zahoor Shah; Takayuki Maruyama; Shuh Narumiya; Sylvain Doré
Journal:  Exp Transl Stroke Med       Date:  2010-07-08

8.  Multipotent adult progenitor cells can suppress graft-versus-host disease via prostaglandin E2 synthesis and only if localized to sites of allopriming.

Authors:  Steven L Highfill; Ryan M Kelly; Matthew J O'Shaughnessy; Qing Zhou; Lily Xia; Angela Panoskaltsis-Mortari; Patricia A Taylor; Jakub Tolar; Bruce R Blazar
Journal:  Blood       Date:  2009-05-20       Impact factor: 22.113

9.  EP2/EP4 signalling inhibits monocyte chemoattractant protein-1 production induced by interleukin 1beta in synovial fibroblasts.

Authors:  R Largo; I Díez-Ortego; O Sanchez-Pernaute; M J López-Armada; M A Alvarez-Soria; J Egido; G Herrero-Beaumont
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

10.  Identification in human airways smooth muscle cells of the prostanoid receptor and signalling pathway through which PGE2 inhibits the release of GM-CSF.

Authors:  Deborah L Clarke; Maria G Belvisi; Matthew C Catley; Magdi H Yacoub; Robert Newton; Mark A Giembycz
Journal:  Br J Pharmacol       Date:  2004-03-15       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.